KR20230066037A - 전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도 - Google Patents
전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도 Download PDFInfo
- Publication number
- KR20230066037A KR20230066037A KR1020237011584A KR20237011584A KR20230066037A KR 20230066037 A KR20230066037 A KR 20230066037A KR 1020237011584 A KR1020237011584 A KR 1020237011584A KR 20237011584 A KR20237011584 A KR 20237011584A KR 20230066037 A KR20230066037 A KR 20230066037A
- Authority
- KR
- South Korea
- Prior art keywords
- ifn
- copd
- exacerbations
- patients
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2014114.9 | 2020-09-08 | ||
| GBGB2014114.9A GB202014114D0 (en) | 2020-09-08 | 2020-09-08 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
| PCT/GB2021/052302 WO2022053792A1 (en) | 2020-09-08 | 2021-09-07 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230066037A true KR20230066037A (ko) | 2023-05-12 |
Family
ID=72841287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237011584A Pending KR20230066037A (ko) | 2020-09-08 | 2021-09-07 | 전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230241177A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210728A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7877300B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230066037A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249545A (cg-RX-API-DMAC7.html) |
| GB (1) | GB202014114D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053792A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030609A (en) | 1995-05-19 | 2000-02-29 | Case Western Reserve University | Method and composition for treating paramyxovirus |
| GB0405634D0 (en) * | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| US7871603B2 (en) | 2007-05-18 | 2011-01-18 | Synairgen Research Limited | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly |
| JP2012512883A (ja) * | 2008-12-19 | 2012-06-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ウイルス感染の治療における上皮成長因子阻害剤の使用 |
| US9421243B2 (en) * | 2010-03-12 | 2016-08-23 | Synairgen Research Limited | Therapy for influenza like illness |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| GB201820659D0 (en) * | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Novel compostions and their use in therapy |
-
2020
- 2020-09-08 GB GBGB2014114.9A patent/GB202014114D0/en not_active Ceased
-
2021
- 2021-09-07 CN CN202180061630.8A patent/CN116249545A/zh active Pending
- 2021-09-07 JP JP2023515363A patent/JP7877300B2/ja active Active
- 2021-09-07 EP EP21777826.5A patent/EP4210728A1/en active Pending
- 2021-09-07 KR KR1020237011584A patent/KR20230066037A/ko active Pending
- 2021-09-07 US US18/024,648 patent/US20230241177A1/en active Pending
- 2021-09-07 WO PCT/GB2021/052302 patent/WO2022053792A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4210728A1 (en) | 2023-07-19 |
| US20230241177A1 (en) | 2023-08-03 |
| GB202014114D0 (en) | 2020-10-21 |
| JP7877300B2 (ja) | 2026-06-22 |
| JP2023540591A (ja) | 2023-09-25 |
| WO2022053792A1 (en) | 2022-03-17 |
| CN116249545A (zh) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11975005B2 (en) | Treatment of respiratory diseases | |
| Mainz et al. | Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis—results of a multicenter, prospective, randomized, double-blind, controlled trial | |
| JP6911044B2 (ja) | 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン2の組合せ | |
| AU2019226190A1 (en) | Methods, compounds and compositions for treatment of influenza and parainfluenza patients | |
| US20220193191A1 (en) | Lipocalin mutein for treatment of asthma | |
| US20220305077A1 (en) | Composition for preventing or treating pulmonary diseases comprising hyaluronan and proteoglycan link protein 1 | |
| JP2021516219A (ja) | ライノウイルス感染症の予防又は治療のための薬物 | |
| US20230241177A1 (en) | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid | |
| US11278598B2 (en) | Methods for treating diseases associated with respiratory viruses | |
| US7871603B2 (en) | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly | |
| JPH06503570A (ja) | 肺の悪性腫瘍類を治療するためのアルファーインターフェロンの経口投与 | |
| CN101365474B (zh) | 用于治疗呼吸道疾病的干扰素λ疗法 | |
| WO2022166885A1 (en) | Recombinant super-compound interferon (rsifn-co) for treating covid-19 patients with or without symptoms | |
| Rimmer et al. | Association of statins with quality of life and olfaction in patients with chronic rhinosinusitis. | |
| CN113384688A (zh) | 一种糜蛋白酶在抗冠状病毒中的应用 | |
| CA2632032C (en) | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly | |
| US20240342239A1 (en) | Treatment of non-cystic fibrosis bronchiectasis | |
| JP2021522263A (ja) | 肺サーファクタントおよびbpdの予防のためのステロイドを含む治療的組合せ | |
| Sirimanne et al. | A Randomized Phase 1 Safety Study of Repeated Doses of Intranasal OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adults: A Potential Treatment for Otitis Media | |
| Başaran et al. | Effect of interferon-alpha therapy on serum IgE, IL-4, and sCD23 levels in childhood asthma | |
| Yao et al. | Tezepelumab. Anti-TSLP (thymic stromal lymphopoietin), Treatment of severe asthma | |
| KR20240033039A (ko) | 호흡기 질환의 치료 | |
| WO2022264097A1 (en) | Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses | |
| JP2023540591A5 (cg-RX-API-DMAC7.html) | ||
| WO2020077251A1 (en) | Treatment of paranasal sinus disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230404 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20240905 Comment text: Request for Examination of Application |